FUTIBATINIB for Cholangiocarcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 77 adverse event reports in the FDA FAERS database where FUTIBATINIB was used for Cholangiocarcinoma.
Most Reported Side Effects for FUTIBATINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 30 | 18.6% | 30 | 9 |
| Diarrhoea | 29 | 18.0% | 4 | 13 |
| Hyperphosphataemia | 22 | 13.7% | 6 | 6 |
| Nausea | 21 | 13.0% | 9 | 12 |
| Disease progression | 20 | 12.4% | 5 | 6 |
| Dry mouth | 18 | 11.2% | 4 | 9 |
| Fatigue | 18 | 11.2% | 6 | 8 |
| Off label use | 16 | 9.9% | 5 | 4 |
| Vomiting | 15 | 9.3% | 5 | 11 |
| Dry eye | 13 | 8.1% | 0 | 5 |
| Constipation | 12 | 7.5% | 2 | 8 |
| Decreased appetite | 12 | 7.5% | 1 | 7 |
| Neuropathy peripheral | 12 | 7.5% | 1 | 7 |
| Asthenia | 11 | 6.8% | 4 | 7 |
| Dehydration | 11 | 6.8% | 5 | 8 |
Other Indications for FUTIBATINIB
Other Drugs Used for Cholangiocarcinoma
GEMCITABINE (1,181)
CISPLATIN (923)
CAPECITABINE (608)
DURVALUMAB (444)
OXALIPLATIN (441)
PEMIGATINIB (431)
FLUOROURACIL (341)
GEMCITABINE\GEMCITABINE (292)
IVOSIDENIB (277)
NIVOLUMAB (250)